Enhanced antitumor effect of dendritic cell based immunotherapy after intratumoral injection of radionuclide Ho-166 against B16 melanoma

Immunology Letters

Volumn 106, Issue 1, 2006, Pages 19-26

  Lee, Tae Hyung ^a   Cho, Young Hun ^a   Lee, Jong Doo ^a   Yang, Woo Ick ^b   Shin, Jong Lan ^a   Lee, Min Geol ^a  

^a Yonsei University   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

Author keywords

Dendritic cell; Holmium; Immunotherapy; Melanoma; Radiotherapy

Indexed keywords

HOLMIUM; HOLMIUM 166; RADIOISOTOPE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER SURVIVAL; CELL ACTIVITY; CELL INFILTRATION; CELL MATURATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; IMMUNE RESPONSE; IMMUNOTHERAPY; IN VITRO STUDY; INFLAMMATORY CELL; LYMPHOCYTE PROLIFERATION; MELANOMA; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR VOLUME;

ANIMALS; ANTIGENS, CD; CELL LINE, TUMOR; DENDRITIC CELLS; FEMALE; IMMUNOTHERAPY; INJECTIONS; KILLER CELLS, NATURAL; MELANOMA; MICE; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; PIPERIDINES; RADIOISOTOPES; SURVIVAL RATE; T-LYMPHOCYTES, CYTOTOXIC; THIAZINES; TISSUE THERAPY;

EID: 33746227735     PISSN: 01652478     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.imlet.2006.03.007     Document Type: Article

References (35)

1. Liu T., and Soong S.J. Epidemiology of malignant melanoma. Surg Clin North Am 76 (1996) 1205-1222
2. de Braud F., Khayat D., Kroon B.B., Valdagni R., Bruzzi P., and Cascinelli N. Malignant melanoma. Crit Rev Oncol Hematol 47 (2003) 35-63
3. Banchereau J., and Steinman R.M. Dendritic cells and the control of immunity. Nature 392 (1998) 245-252
4. Kim C.J., Dessureault S., Gabrilovich D., Reintgen D.S., and Slingluff Jr. C.L. Immunotherapy for melanoma. Cancer Control 9 (2002) 22-30
5. Whiteside T.L., and Odoux C. Dendritic cell biology and cancer therapy. Cancer Immunol Immunother 53 (2004) 240-248
6. Wright-Browne V., McClain K.L., Talpaz M., Ordonez N., and Estrov Z. Physiology and pathophysiology of dendritic cells. Hum Pathol 28 (1997) 563-579
7. Chen Z., Moyana T., Saxena A., Warrington R., Jia Z., and Xiang J. Efficient antitumor immunity derived from maturation of dendritic cells that had phagocytosed apoptotic/necrotic tumor cells. Int J Cancer 93 (2001) 539-548
8. Morse M.A., Deng Y., Coleman D., Hull S., Kitrell-Fisher E., Nair S., et al. A Phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen. Clin Cancer Res 5 (1999) 1331-1338
9. Nestle F.O., Alijagic S., Gilliet M., Sun Y., Grabbe S., Dummer R., et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 4 (1998) 328-332
10. Ragde H., Cavanagh W.A., and Tjoa B.A. Dendritic cell based vaccines: progress in immunotherapy studies for prostate cancer. J Urol 172 (2004) 2532-2538
11. Timmerman J.M., Czerwinski D.K., Davis T.A., Hsu F.J., Benike C., Hao Z.M., et al. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood 99 (2002) 1517-1526
12. Minev B.R. Melanoma vaccines. Semin Oncol 29 (2002) 479-493
13. Kusmartsev S., and Gabrilovich D.I. Immature myeloid cells and cancer-associated immune suppression. Cancer Immunol Immunother 51 (2002) 293-298
14. Ohm J.E., and Carbone D.P. VEGF as a mediator of tumor-associated immunodeficiency. Immunol Res 23 (2001) 263-272
15. Oyama T., Ran S., Ishida T., Nadaf S., Kerr L., Carbone D.P., et al. Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kappa B activation in hemopoietic progenitor cells. J Immunol 160 (1998) 1224-1232
16. Dudley M.E., and Rosenberg S.A. Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer 3 (2003) 666-675
17. Mapara M.Y., and Sykes M. Tolerance and cancer: mechanisms of tumor evasion and strategies for breaking tolerance. J Clin Oncol 22 (2004) 1136-1151
18. Melcher A., Todryk S., Bateman A., Chong H., Lemoine N.R., and Vile R.G. Adoptive transfer of immature dendritic cells with autologous or allogeneic tumor cells generates systemic antitumor immunity. Cancer Res 59 (1999) 2802-2805
19. Almand B., Resser J.R., Lindman B., Nadaf S., Clark J.I., Kwon E.D., et al. Clinical significance of defective dendritic cell differentiation in cancer. Clin Cancer Res 6 (2000) 1755-1766
20. Kiertscher S.M., Luo J., Dubinett S.M., and Roth M.D. Tumors promote altered maturation and early apoptosis of monocyte-derived dendritic cells. J Immunol 164 (2000) 1269-1276
21. Pawelec G., Heinzel S., Kiessling R., Muller L., Ouyang Q., and Zeuthen J. Escape mechanisms in tumor immunity: a year 2000 update. Crit Rev Oncog 11 (2000) 97-133
22. Friedman E.J. Immune modulation by ionizing radiation and its implications for cancer immunotherapy. Curr Pharm Des 8 (2002) 1765-1780
23. Deacon J., Peckham M.J., and Steel G.G. The radioresponsiveness of human tumours and the initial slope of the cell survival curve. Radiother Oncol 2 (1984) 317-323
24. Konefal J.B., Emami B., and Pilepich M.V. Analysis of dose fractionation in the palliation of metastases from malignant melanoma. Cancer 61 (1998) 243-246
25. Rofstad E.K. Fractionation sensitivity (alpha/beta ratio) of human melanoma xenografts. Radiother Oncol 33 (1994) 133-138
26. Cooper J.S. Radiation therapy of malignant melanoma. Dermatol Clin 20 (2002) 713-716
27. Jenrette J.M. Malignant melanoma: the role of radiation therapy revisited. Semin Oncol 23 (1996) 759-762
28. Sause W.T., Cooper J.S., Rush S., Ago C.T., Cosmatos D., Coughlin C.T., et al. Fraction size in external beam radiation therapy in the treatment of melanoma. Int J Radiat Oncol Biol Phys 20 (1991) 429-432
29. Firusian N., and Dempke W. An early phase II study of intratumoral P-32 chromic phosphate injection therapy for patients with refractory solid tumors and solitary metastases. Cancer 85 (1999) 980-987
30. McCready V.R., and Cornes P. The potential of intratumoural unsealed radioactive source therapy. Eur J Nucl Med 28 (2001) 567-579
31. Lee J.D., Yang W.I., Lee M.G., Ryu Y.H., Park J.H., Shin K.H., et al. Effective local control of malignant melanoma by intratumoural injection of a beta-emitting radionuclide. Eur J Nucl Med Mol Imaging 29 (2002) 221-230
32. Nikitina E.Y., and Gabrilovich D.I. Combination of gamma-irradiation and dendritic cell administration induces a potent antitumor response in tumor-bearing mice: approach to treatment of advanced stage cancer. Int J Cancer 94 (2001) 825-833
33. Teitz-Tennenbaum S., Li Q., Rynkiewicz S., Ito F., Davis M.A., McGinn C.J., et al. Radiotherapy potentiates the therapeutic efficacy of intratumoral dendritic cell administration. Cancer Res 63 (2003) 8466-8475
34. Coleman C.N., and Stevenson M.A. Biologic basis for radiation oncology. Oncology 10 (1996) 399-411
35. Albertsson P.A., Basse P.H., Hokland M., Goldfarb R.H., Nagelkerke J.F., Nannmark U., et al. NK cells and the tumour microenvironment: implications for NK-cell function and anti-tumour activity. Trends Immunol 24 (2003) 603-609